Vystar Adds Fluid Energy Conversion Into Planned RxAir Spin-Off
20 sept. 2021 08h30 HE
|
Vystar Corp.
FEC patented technology has potential for applications in multiple industriesFEC to prioritize air and water purification R&D Worcester, MA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Vystar®...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
16 sept. 2021 07h30 HE
|
Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
Vystar Details Preliminary Plans for RxAir Spin Off as Shareholder Dividend
05 août 2021 08h00 HE
|
Vystar Corp.
Separation of RxAir® business offers pure-play investment opportunityVystar shareholders on the Record Date of January 5, 2022 to qualify for dividend of RxAir NewCo shares Worcester,...
AB Science annonce la publication d’un article dans la revue de renommée mondiale Science qui confirme le potentiel du masitinib comme traitement de la Covid-19 avec une activité antivirale contre le SARS-CoV-2 et tous ses variants testés
20 juil. 2021 12h08 HE
|
AB Science
COMMUNIQUE DE PRESSE PUBLICATION DANS LA REVUE DE RENOMMÉE MONDIALE SCIENCE CONFIRMANT LE POTENTIEL DU MASITINIB COMME TRAITEMENT DE LA COVID-19 AVEC UNE ACTIVITÉ ANTIVIRALE CONTRE LE SARS-COV-2...
AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern
20 juil. 2021 12h08 HE
|
AB Science
PRESS RELEASE PUBLICATION IN THE WORLD-RENOWNED JOURNAL SCIENCE CONFIRMS POTENTIAL OF MASITINIB AS A TREATMENT OF COVID-19 WITH ANTI-VIRAL ACTIVITY AGAINST SARS-COV-2 AND ALL TESTED VARIANTS OF...
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium
18 juin 2021 09h30 HE
|
Innovation Pharmaceuticals Inc.
Presentation to be part of the “Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases” Breakout Session WAKEFIELD, Mass., June 18, 2021 (GLOBE NEWSWIRE)...
Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19
03 juin 2021 07h00 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that it has achieved full...
Vystar Partners with “Nothing in the Air” for RxAir Marketing, Advertising & Distribution
02 juin 2021 08h30 HE
|
Vystar Corp.
NITA president one of nation’s top 100 TV healthcare content producersLaunching ROKU Campaign June 3 Worcester, MA and PALM DESERT, CA, June 02, 2021 (GLOBE NEWSWIRE) -- Vystar® Corporation’s...
Vystar Posts Highest Revenue & Profit in Company History in First Quarter 2021
24 mai 2021 08h30 HE
|
Vystar Corp.
Increased revenue from RxAir® UV light air purifiers that destroy more than 99.6% of airborne viruses and bacteriaRecord revenue from Rotmans Furniture “Closing to Remodel” Sales EventIncreased gross...
Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
05 avr. 2021 07h30 HE
|
Innovation Pharmaceuticals Inc.
Study drug dosing regimen to increase to 5 days (from 3 days) based on DMC recommendationEnrollment has reached 25 percent in the Company’s ~120-patient Phase 2 COVID-19 clinical trial WAKEFIELD,...